Covid-19 in Lupus Patients

Manifestations Related to Covid-19 in Patients With Systemic Lupus Erythematosus

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04355702

Enrollment

130

Registered

2020-04-21

Start date

2020-03-01

Completion date

2020-12-30

Last updated

2021-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19, Systemic Lupus Erythematosus

Keywords

Systemic lupus erythematosus, Hydroxychloroquine

Brief summary

The Covid-19 pandemic is a major public health issue. Potential treatments are essential to control the infection. Hydroxychlorquine is currently tested in several clinical trials to evaluate its efficiency.The objective of this study was to evaluate the symptoms related to COVID-19 occuring in patients with systemic lupus erythematosus (SLE)

Detailed description

Introduction:The Covid-19 pandemic has had a major impact on many countries on the sanitary and economic level. Finding an efficient cure is paramount in order to reduce its severity and mortality. Several medications are currently under investigation. Among them, hydroxychloroquine can prevent viral replication at several sites and has been shown efficient in vitro. Several clinical trials are in progress to evaluate its efficiency in vivo. However, no study so far has evaluated the covid-19 infection in patients with SLE. Objectives and methods: The primary objective was to describe the prevalence and the severity of Covid-19 infection in patients wih systemic lupus erythematosus. The secondary objective was to compare these parameters in patients treated by hydroxychloroquine and those not treated by hydroxychloroquine. This observational study of a historical-prospective cohort focuses on all adult lupus patients seen during the last year in the departments of rheumatology and nephrology in CHU Montpellier. It will collect information concerning the patient's condition, treatments and main comorbidities (cardio-vascular, respiratory, hepatic and immune depression), as well as symptoms suggesting covid-19 infection, its confirmation and its course and severity.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

\- adult patient with systemic lupus erythematosus seen during the last year in the departments of rheumatology or nephrology

Exclusion criteria

\- patient not speaking french nor english

Design outcomes

Primary

Measure	Time frame	Description
prevalence and severity of Covid-19 infection in patients with SLE	1 day	prevalence and severity of Covid-19 infection in patients with SLE

Secondary

Measure	Time frame	Description
prevalence and severity of Covid-19 infection in patients treated by hydroxychloroquine	1 day	prevalence and severity of Covid-19 infection in patients treated by hydroxychloroquine

Countries

France

Outcome results